Melatonin modulation of cross­talk among malignant epithelial, endothelial and adipose cells in breast cancer (Review)

Cos,Samuel; Álvarez‑García,Virginia; González,Alicia; Alonso‑González,Carolina

doi:10.3892/ol.2014.2203

Melatonin modulation of crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer (Review)

Authors:
- Samuel Cos
- Virginia Álvarez‑García
- Alicia González
- Carolina Alonso‑González
View Affiliations

Affiliations: Department of Physiology and Pharmacology, School of Medicine, University of Cantabria and Valdecilla Research Institute, Santander 39011, Spain
Published online on: May 30, 2014 https://doi.org/10.3892/ol.2014.2203
Pages: 487-492

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Melatonin, the main secretory product of the pineal gland, is an oncostatic agent that reduces the growth and development of various types of tumors, particularly mammary tumors whose growth is dependent on estrogens. Previous in vivo and in vitro studies point to the hypothesis that melatonin interplays with estrogen signaling pathways at three different levels: i) an indirect mechanism, by interfering with the hypothalamic‑pituitary‑reproductive axis in such way that the level of plasma estrogens synthesized by the gonadal glands are downregulated; ii) a direct mechanism of the pineal gland at the cell cancer level, disrupting the activation of estradiol receptors, therefore behaving as a selective estrogen receptor modulator; and iii) by regulating the enzymes involved in the biosynthesis of estrogens in other tissues, thus behaving as a selective estrogen enzyme modulator. The intratumoral metabolism and synthesis of estrogens, as a result of the interactions of various enzymes, is more important than blood uptake to maintain mammary gland estrogen levels in menopausal females. Additionally, estrogens are considered to play an important role in the pathogenesis and development of hormone‑dependent breast carcinoma. Paracrine interactions among malignant epithelial cells and proximal adipose and endothelial cells, through cytokines and growth factors produced by breast tumor cells, modulate estrogen production at the mammary tumor level and, as a consequence, the genesis and development of mammary tumors. The aim of the present review is to summarize the recent findings describing the mechanisms by which melatonin is able to modulate the crosstalk among malignant epithelial, endothelial and adipose cells in breast cancer.

View Figures

View References

1	Cos S and Sánchez-Barceló EJ: Melatonin and mammary pathological growth. Front Neuroendocrinol. 21:133–170. 2000.
2	Cos S and Sánchez-Barceló EJ: Melatonin, experimental basis for a possible application in breast cancer prevention and treatment. Histol Histopathol. 15:637–647. 2000.
3	Blask DE, Sauer LA and Dauchy RT: Melatonin as a chronobiotic/anticancer agent: cellular, biochemical and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Topics Med Chem. 2:113–132. 2002.
4	Sánchez-Barceló EJ, Cos S, Fernández R and Mediavilla MD: Melatonin and mammary cancer: a short review. Endocr Relat Cancer. 10:153–159. 2003.
5	Sánchez-Barceló EJ, Cos S, Mediavilla MD, Martínez-Campa CM, González A and Alonso-González C: Melatonin-estrogen interactions in breast cancer. J Pineal Res. 38:217–222. 2005.
6	Cohen M, Lippman M and Chabner B: Role of pineal gland in aetiology and treatment of breast cancer. Lancet. 2:814–816. 1978.
7	Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev. 30:118–128. 2006.
8	Reiter RJ: The pineal and its hormones in the control of reproduction in mammals. Endocr Rev. 1:109–131. 1980.
9	Molis TM, Spriggs LL and Hill SM: Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol. 8:1681–1690. 1994.
10	Cos S, Blask DE, Lemus-Wilson A and Hill SM: Effects of melatonin on the cell cycle kinetics and estrogen rescue of MCF-7 human breast cancer cells in culture. J Pineal Res. 10:36–42. 1991.
11	Hill SM, Spriggs LL, Simon MA, Muraoka H and Blask DE: The growth inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett. 64:249–256. 1992.
12	Cos S, Martínez-Campa C, Mediavilla MD and Sánchez-Barceló EJ: Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res. 38:136–142. 2005.
13	González A, Martínez-Campa C, Mediavilla MD, et al: Effects of MT1 melatonin receptor overexpression on the aromatase-suppressive effect of melatonin in MCF-7 human breast cancer cells. Oncol Rep. 17:947–955. 2007.
14	Cos S, González A, Güezmes A, Mediavilla MD, Martínez-Campa C, Alonso-González C and Sánchez-Barceló EJ: Melatonin inhibits the growth of DMBA-induced mammary tumors by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer. 118:274–278. 2006.
15	Martínez-Campa C, González A, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ and Cos S: Melatonin enhances the inhibitory effect of aminoglutethimide on aromatase activity in MCF-7 human breast cancer cells. Breast Cancer Res Treat. 94:249–254. 2005.
16	Simpson ER: Role of aromatase in sex steroid action. J Mol Endocrinol. 25:149–156. 2000.
17	van Landeghem AA, Poortman J, Nabuurs M and Thijssen JH: Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res. 45:2900–2906. 1985.
18	Pasqualini JR: The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta. 1654:123–143. 2004.
19	Pasqualini JR and Chetrite GS: Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J Steroid Biochem Mol Biol. 93:221–236. 2005.
20	Conley A and Hinshelwood M: Mammalian aromatases. Reproduction. 121:685–695. 2001.
21	Santen RJ and Harvey HA: Use of aromatase inhibitors in breast carcinoma. Endocr Relat Cancer. 6:75–92. 1999.
22	Suzuki T, Miki Y, Nakamura Y, et al: Sex steroid-producing enzymes in human breast cancer. Endocr Relat Cancer. 12:701–720. 2005.
23	Cos S, González A, Álvarez-García V, Alonso-González C and Martínez-Campa C: Melatonin and breast cancer: selective estrogen enzyme modulator. Advances in Cancer Drug Targets. Atta-ur-Rahman: 1. 1st Edition. Bentham Science Publishers; Sharjah (UAE): pp. 207–237. 2012
24	González A, Cos S, Martínez-Campa C, Alonso-González C, Sánchez-Mateos S, Mediavilla MD and Sánchez-Barceló EJ: Selective estrogen enzyme modulator actions of melatonin in human breast cancer cells. J Pineal Res. 45:86–92. 2008.
25	Bulun SE, Lin Z, Imir G, et al: Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev. 57:359–383. 2005.
26	Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H and Shozu M: The human CYP19 (aromatase p450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol. 86:219–224. 2003.
27	Díaz-Cruz ES, Shapiro CL and Brueggemeier RW: Cyclooxygenase inhibitors suppress aromatase expression and activity in breast cancer cells. J Clin Endocrinol Metab. 90:2563–2570. 2005.
28	Prosperi JR and Robertson FM: Cyclooxygenase-2 directly regulates gene expression of P450 Cyp19 aromatase promoter regions pII, pI. 3 and pI7 and estradiol production in human breast tumor cells. Prostaglandins Other Lipid Mediat. 81:55–70. 2006.
29	Martínez-Campa C, González A, Mediavilla MD, Alonso-González, Álvarez-García V, Sánchez-Barceló EJ and Cos S: Melatonin inhibits aromatase promoter expression by regulating cyclooxygenases expression and activity in breast cancer cells. Br J Cancer. 101:1613–1619. 2009.
30	Wang J, Xiao X, Zhang Y, et al: Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J Pineal Res. 53:77–90. 2012.
31	González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ and Cos S: Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expresión in rat glioma cells. Br J Cancer. 97:755–760. 2007.
32	González A, Martínez-Campa C, Mediavilla MD, Alonso-González C, Álvarez-García V, Sánchez-Barceló EJ and Cos S: Inhibitory effects of melatonin on sulfatase and 17β-hydroxysteroid dehydrogenase activity and expression in glioma cells. Oncol Rep. 23:1173–1178. 2010.
33	González A, Álvarez-García V, Martínez-Campa C, Mediavilla MD, Alonso-González C, Sánchez-Barceló EJ and Cos S: In vivo inhibition of the estrogen sulfatase enzyme and growth of DMBA-induced mammary tumors by melatonin. Curr Cancer Drug Tar. 10:279–286. 2010.
34	Meng L, Zhou J, Sasano H, Suzuki T, Zeitoun KM and Bulun SE: Tumor necrosis factor α and interleukin 11 secreted by malignant breast epitelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein α and peroxisome proliferator-activated receptor γ: mechasnism of desmoplastic reaction. Cancer Res. 61:2250–2255. 2001.
35	Bulun SE, Chen D, Lu M, et al: Aromatase excess in cancers of breast, endometrium and ovary. J Steroid Biochem Mol Biol. 106:81–96. 2007.
36	Ntambi JM and Kim YC: Adipocyte differentiation and gene expression. J Nutr. 130:3122S–3126S. 2000.
37	González A, Álvarez-García V, Martínez-Campa C, Alonso-González C and Cos S: Melatonin promotes differentiation of 3T3-L1 fibroblasts. J Pineal Res. 52:12–20. 2012.
38	Knower KC, To SQ, Takagi K, et al: Melatonin suppresses aromatase expression and activity in breast cancer associated fibroblasts. Breast Cancer Res Treat. 132:765–771. 2012.
39	Álvarez-García V, González A, Alonso-González C, Martínez-Campa C and Cos S: Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. J Pineal Res. 52:282–290. 2012.
40	Harada N, Sasano H, Murakami H, Ohkuma T, Nagura H and Takagi Y: Localized expression of aromatase in human vascular tissues. Circ Res. 84:1285–1291. 1999.
41	Mukherjee TK, Dinh H, Chaudhuri G and Nathan L: Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Proc Nat Acad Sci USA. 6:4055–4060. 2002.
42	Sebastian S, Takayama K, Shozu M and Bulun SE: Cloning and characterization of a novel endothelial promoter of the human CYP19 (aromatase P450) gene that is upregulated in breast cancer tissue. Mol Endocrinol. 10:2243–2254. 2001.
43	Senger DR, Van De Water L, Brown LF, et al: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 12:303–324. 1993.
44	Liang Y and Hyder SM: Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. Endocrinology. 146:3632–3641. 2005.
45	Álvarez-García V, González A, Martínez-Campa C, Alonso-González C and Cos S: Melatonin modulates aromatase activity and expression in endotelial cells. Oncol Rep. 29:2058–2064. 2013.
46	Álvarez-García V, González A, Alonso-González C, Martínez-Campa C and Cos S: Regulation of vascular endotelial growth factor by melatonin in human breast cáncer cells. J Pineal Res. 54:373–380. 2013.
47	Álvarez-García V, González A, Alonso-González C, Martínez-Campa C and Cos S: Antiangiogenic effects of melatonin in endotelial cell cultures. Microvasc Res. 87:25–33. 2013.